Strategic Clarity for Psychedelic Healthcare’s Mainstream Adoption
Why Attend a Delphi Insight Session?
- Strategic Impact: Maximize your influence on the ethical integration of psychedelic therapies. Our insights support leaders in the psychedelic field and those in finance, healthcare, and government who seek to navigate and shape this emerging landscape, ensuring your efforts contribute to meaningful, systemic change.
- Unparalleled Clarity: Cut through complexity. We deliver concise, actionable intelligence on the psychedelic ecosystem, Delphi’s pivotal role in building its infrastructure, and the critical pathways to responsible mainstream adoption, respecting your time and expertise.
- Bridging Perspectives: Gain a holistic view of how psychedelic therapies can be integrated with established systems. We translate critical information and foster coherence between the psychedelic field and incumbent decision-makers across healthcare, finance, and policy, paving the way for informed action and mutually beneficial outcomes.
Upcoming Delphi Insight Sessions
Join us every first Wednesday of the month as we discuss building a robust infrastructure for psychedelic therapies.
Each 30-minute session, followed by a 15-minute Q&A, offers strategic insights, updates on Delphi’s work, special guests, and opportunities for collaboration.
Time: 11:00 AM MT (1:00 PM ET / 10:00 AM PT)
Insight Session #1 | June 4, 2025
Our first insight session offered an introduction to Delphi, our mission to bridge emerging psychedelic therapies with established healthcare systems, and our vision for their safe, equitable, and effective integration.
We discussed the critical ‘behind-the-scenes’ work required for psychedelic therapies to transition from promise to practice, emphasizing Delphi’s role in creating the ‘connective tissue’ needed for coherence between the psychedelic field and existing systems, such as insurance, government, and healthcare delivery.
The session highlighted key Delphi projects, each designed to provide decision-makers with essential data, non-advocacy education, and ecosystem clarity for the responsible rollout of these transformative treatments.
